| Vol. 11.40 – 20 October, 2020 |
| |
|
|
| Researchers FACS-purified epithelial cells from human pancreatic ductal adenocarcinoma and normal pancreas and derived their genome-wide transcriptome and DNA methylome landscapes. [Cancer Discovery] |
| | | |
|
|
| Scientists found a consistent, abnormal methylation pattern in insulinomas. They found that abnormal insulin (INS) promoter methylation and altered transcription factor expression created alternative drivers of INS expression, replacing canonical PDX1-driven beta cell specification with a pathological, looping, distal enhancer-based form of transcriptional regulation. [Nature Communications] |
|
|
|
| Researchers present an automated, high-throughput, microfluidic 3D organoid culture and analysis system to facilitate preclinical research and personalized therapies. They validated the system by performing individual, combinatorial, and sequential drug screens on human-derived pancreatic tumor organoids. [Nature Communications] |
|
|
|
| miR-124 or EZH2 was overexpressed in AsPC-1 and PANC1 cells. Then, the effects on cell viability, apoptosis, invasion, migration and epithelial mesenchymal transition were evaluated. The roles of miR-124 on the expression and function of EZH2 in pancreatic tumors were determined by dual luciferase reporter assay. [Aging] |
|
|
|
| Several in vitro and in vivo mechanisms involved in PDAC metastases were investigated following treatment with P-AscH−. Serum from PDAC patients in clinical trials with P-AscH− were tested for the presence and quantity of circulating tumor cell-derived nucleases. [Scientific Reports] |
|
|
|
| Investigators showed interlukine-17 receptor B (IL-17RB) expression was positively correlated with mucin 1 (MUC1) and MUC4 expression in pancreatic cancer cells and tumor tissue. [Scientific Reports] |
|
|
|
| In CFPAC-I and HPAF-II pancreatic cancer cell lines, the combined in vitro effect of tumor treating fields and radiotherapy was evaluated by measuring cell counts, markers of apoptosis, and clonogenic cell survival. [International Journal of Radiation Biology] |
| |
|
|
| Researchers showed that SPARC enhanced the promoting effect of Muscarinic receptor agonist oxotremorine-M on insulin secretion in cultured mouse islets. Overexpression of SPARC down-regulated RGS4, a negative regulator of β-cell M3 muscarinic receptors. [Scientific Reports] |
| |
|
|
|
| The authors focus on three types of well-established non-coding RNAs — miRNAs, long non-coding RNAs, and circular RNAs— and discuss their potential as diagnostic, prognostic and predictive biomarkers in pancreatic ductal adenocarcinoma. [Seminars in Cancer Biology] |
|
|
|
| Scientists present the AMP-activated protein kinase (AMPK) role in eukaryotic cells and focus on the relationship between AMPK activity and the regulation of base excision repair system through its main component—8-oxoguanine glycosylase [Molecular Biology Reports] |
|
|
|
|
| Apexigen, Inc. announced that the US FDA has granted orphan drug designation status to APX005M for the treatment of esophageal and gastroesophageal junction cancer and for the treatment of pancreatic cancer. [Apexigen Inc.] |
|
|
|
| The Pancreatic Cancer Action Network announced the launch of Precision PromiseSM, the first of its kind adaptive clinical trial platform for pancreatic cancer patients. [Pancreatic Cancer Action Network (PR Newswire, LLC)] |
|
|
|
|
| January 25 – January 28, 2021 Virtual |
|
|
|
|
|
| Karolinska Institutet – Huddinge, Sweden |
|
|
|
| Roswell Park Cancer Center – Buffalo, New York, United States |
|
|
|
| Van Andel Institute – Grand Rapids, Michigan, United States |
|
|
|
| The Mayo Clinic – Jacksonville, Florida, United States |
|
|
|
| University of Pittsburgh School of Medicine – Pittsburgh, Pennsylvania, United States |
|
|
|
|